Efficacy of Atomoxetine Versus Placebo in School-Age Girls With Attention-Deficit/Hyperactivity Disorder
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective. The efficacy of atomoxetine was assessed in school-age girls with attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporter with minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors. Methods. A total of 291 children who were 7 to 13 years of age and met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for ADHD participated in 1 of 2 combined, double-blind, placebo-controlled, multisite, identical clinical trials. This intent-to-treat subset analysis examined the effects of atomoxetine versus placebo in 51 girls who were randomized to atomoxetine (n = 30) or placebo (n = 21) for 9 weeks. ADHD symptoms were assessed using parent- and investigator-rated scales. Results. Atomoxetine was superior to placebo on the following measures: the Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score; the Inattentive and Hyperactive/Impulsive subscales of the Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score; the ADHD Index subscale of the Conners’ Parent Rating Scale-Revised: Short Form; and the Clinical Global Impressions of Severity of ADHD. Statistically significant efficacy was seen 1 week after randomization and remained so for the duration of the study. One patient from each of the atomoxetine and placebo groups discontinued the study as a result of an adverse event. Conclusion. Atomoxetine was found to be effective and well tolerated for the treatment of ADHD in school-age girls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Conners, C. K., Sitarenios, G., Parker, J. D. A., & Epstein, J. N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022602400621 · Cited by 1,772
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.564 · Cited by 1,738
Self-citationGender Differences in ADHD: A Meta-Analysis and Critical Review
GAUB, M., & CARLSON, C. L. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199708000-00011 · Cited by 1,117
Biederman, J., Mick, E., Faraone, S. V., Braaten, E., Doyle, A., Spencer, T., Wilens, T. E., Frazier, E., & Johnson, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.36 · Cited by 863
Self-citationMichelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Self-citationBIEDERMAN, J., FARAONE, S. V., MICK, E., WILLIAMSON, S., WILENS, T. E., SPENCER, T. J., WEBER, W., JETTON, J., KRAUS, I., PERT, J., et al. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199908000-00012 · Cited by 364
Self-citation
Cited by
Cumulative risk and child development.
Evans, G. W., Li, D., & Whipple, S. S. (2013) · Psychological Bulletin · doi:10.1037/a0031808 · Cited by 2,024
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
ARNOLD, L. E., AMAN, M. G., COOK, A. M., WITWER, A. N., HALL, K. L., THOMPSON, S., & RAMADAN, Y. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231976.28719.2a · Cited by 260
“In a larger nonautistic sample (57 girls ages 6Y12), Biederman et al. (2006) found significant improvement in number of problems attempted on a timed arithmetic task, although significantly less than with amphetamine in the 18-day trial.”
BackgroundComparing the efficacy of medications for ADHD using meta-analysis.
(2006) · PubMed Central · Cited by 230
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
Allen, A. J., Kurlan, R. M., Gilbert, D. L., Coffey, B. J., Linder, S. L., Lewis, D. W., Winner, P. K., Dunn, D. W., Dure, L. S., Sallee, F. R., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000188869.58300.a7 · Cited by 225
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185
“Biederman et al. (2002) found atomoxetine to be efficacious and well tolerated in school-age girls, but there was no comparison between boys *p<0.05 and girls.”
BackgroundInfluentialNon?stimulant medications in the treatment of ADHD
Banaschewski, T., Roessner, V., Dittmann, R. W., Janardhanan Santosh, P., & Rothenberger, A. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1010-x · Cited by 183
“ADHD symptoms in both boys and girls respond to atomoxetine [22].”
BackgroundSelf-citationReed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
The Atomoxetine ADHD and Comorbid MDD Study Group:, Bangs, M. E., Emslie, G. J., Spencer, T. J., Ramsey, J. L., Carlson, C., Bartky, E. J., Busner, J., Duesenberg, D. A., Harshawat, P., et al. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0066 · Cited by 103
“Other studies have reported a 34–51% decrease from baseline in the ADHDRS-Par-ent:Inv total scores after 7–10 weeks of treat-ment (Michelson et al. 2001; Biederman et al. 2002; Kratochvil et al. 2002; Michelson et al. 2002; Spencer et al. 2002; Kelsey et al. 2004; Weiss et al. 2005).”
InfluentialSelf-citationThe female side of pharmacotherapy for ADHD—A systematic literature review
Kok, F. M., Groen, Y., Fuermaier, A. B. M., & Tucha, O. (2020) · PLOS ONE · doi:10.1371/journal.pone.0239257 · Cited by 86
“Study designs differed as well; ranging from setting, such as classrooms [70, 74, 77], in—and outpatient centers [5,71,80,81], to experimental laboratory [72].”
BackgroundMethodInfluentialWang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y.-J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057767 · Cited by 84
Pozzi, M., Carnovale, C., Peeters, G. G. A. M., Gentili, M., Antoniazzi, S., Radice, S., Clementi, E., & Nobile, M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.05.021 · Cited by 56
Atomoxetine facilitates attentional set shifting in adolescent rats
Cain, R. E., Wasserman, M. C., Waterhouse, B. D., & McGaughy, J. A. (2011) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2011.04.003 · Cited by 55
“, 2007) are used to treat ADHD (Biederman et al., 2002; Chamberlain et al., 2007; Christman et al., 2004; Kratochvil, Vaughn, Harrington, & Burke, 2003; Kratochvil et al., 2006; Newcorn et al., 2008; Newman et al., 2008) or improve cognition in normal subjects (Berridge & Waterhouse, 2003; Chamberlain et al.”
Dell'Agnello, G., Maschietto, D., Bravaccio, C., Calamoneri, F., Masi, G., Curatolo, P., Besana, D., Mancini, F., Rossi, A., Poole, L., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.07.008 · Cited by 54
“…in children, adolescents and adults, atomoxetine consistently reduced symptoms of ADHD (Spencer et al., 1998; Michelson et al., 2001, 2002; Biederman et al., 2002; Weiss et al., 2005) and positive outcomes have also been reported in family and social functioning of children and…”
Charnsil, C. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710376907 · Cited by 36
Takahashi, M., Takita, Y., Yamazaki, K., Hayashi, T., Ichikawa, H., Kambayashi, Y., Koeda, T., Oki, J., Saito, K., Takeshita, K., et al. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0154 · Cited by 36
Changes in Emotions Related to Medication Used to Treat ADHD. Part I: Literature Review
Manos, M. J., Brams, M., Childress, A. C., Findling, R. L., López, F. A., & Jensen, P. S. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710381230 · Cited by 28
“Of these, 47 (Ahmann et al., 1993, 2001; Arnold et al., 2004; Barkley, McMurray, Edelbrock, & Robbins, 1990; Biederman, Boellner, et al., 2007; Biederman et al., 2002, 2008; Biederman, Krishnan, Zhang, McGough, & Findling, 2007; Chacko et al., 2005; Daviss et al., 2008; Findling et al., 2008; Fine…”
BackgroundInfluential
Metadata
- Authors
- Biederman, J., Heiligenstein, J. H., Faries, D. E., Galil, N., Dittmann, R., Emslie, G. J., Kratochvil, C. J., Laws, H. F., Schuh, K. J., & Atomoxetine ADHD Study Group
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2002-12-01
- Volume
- 110
- Issue
- 6
- Pages
- e75-e75
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2120948822
- Cited by
- 87
- References
- 8
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.